Literature DB >> 26902963

Clinical trials: New drug for pancreatic cancer highlights the dual effect of regulatory approvals.

Susan E Bates1, Tito Fojo1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 26902963     DOI： 10.1038/nrclinonc.2016.22

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Predicting Low Accrual in the National Cancer Institute's Cooperative Group Clinical Trials.

Authors:  Caroline S Bennette; Scott D Ramsey; Cara L McDermott; Josh J Carlson; Anirban Basu; David L Veenstra
Journal:  J Natl Cancer Inst       Date:  2015-12-29       Impact factor: 13.506

2.  Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.

Authors:  Andrea Wang-Gillam; Chung-Pin Li; György Bodoky; Andrew Dean; Yan-Shen Shan; Gayle Jameson; Teresa Macarulla; Kyung-Hun Lee; David Cunningham; Jean F Blanc; Richard A Hubner; Chang-Fang Chiu; Gilberto Schwartsmann; Jens T Siveke; Fadi Braiteh; Victor Moyo; Bruce Belanger; Navreet Dhindsa; Eliel Bayever; Daniel D Von Hoff; Li-Tzong Chen
Journal:  Lancet       Date:  2015-11-29       Impact factor: 79.321

3.  Chemotherapy: NAPOLI-1: winning scoop for metastatic pancreatic cancer.

Authors:  Lisa Hutchinson
Journal:  Nat Rev Clin Oncol       Date:  2015-12-15       Impact factor: 66.675

4.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

5.  Advancing Clinical Trials to Streamline Drug Development.

Authors:  Susan E Bates; Donald A Berry; Sanjeeve Balasubramaniam; Stuart Bailey; Patricia M LoRusso; Eric H Rubin
Journal:  Clin Cancer Res       Date:  2015-10-15       Impact factor: 12.531

Review 6.  Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology.

Authors:  B Glimelius; M Lahn
Journal:  Ann Oncol       Date:  2011-01-13       Impact factor: 32.976

Review 7.  FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity.

Authors:  Krishna S Gunturu; Xiaopan Yao; Xiangyu Cong; Jaykumar R Thumar; Howard S Hochster; Stacey M Stein; Jill Lacy
Journal:  Med Oncol       Date:  2012-12-28       Impact factor: 3.064

8.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

Authors:  Daniel D Von Hoff; Thomas Ervin; Francis P Arena; E Gabriela Chiorean; Jeffrey Infante; Malcolm Moore; Thomas Seay; Sergei A Tjulandin; Wen Wee Ma; Mansoor N Saleh; Marion Harris; Michele Reni; Scot Dowden; Daniel Laheru; Nathan Bahary; Ramesh K Ramanathan; Josep Tabernero; Manuel Hidalgo; David Goldstein; Eric Van Cutsem; Xinyu Wei; Jose Iglesias; Markus F Renschler
Journal:  N Engl J Med       Date:  2013-10-16       Impact factor: 91.245

9.  Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort.

Authors:  Alix Portal; Simon Pernot; David Tougeron; Claire Arbaud; Anne Thirot Bidault; Christelle de la Fouchardière; Pascal Hammel; Thierry Lecomte; Johann Dréanic; Romain Coriat; Jean-Baptiste Bachet; Olivier Dubreuil; Lysiane Marthey; Laetitia Dahan; Belinda Tchoundjeu; Christophe Locher; Céline Lepère; Franck Bonnetain; Julien Taieb
Journal:  Br J Cancer       Date:  2015-09-15       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.